182 related articles for article (PubMed ID: 8699235)
1. Adoptive immunotherapy using lymphokine-activated killer (LAK) cells and interleukin-2 for recurrent malignant primary brain tumors.
Sankhla SK; Nadkarni JS; Bhagwati SN
J Neurooncol; 1996 Feb; 27(2):133-40. PubMed ID: 8699235
[TBL] [Abstract][Full Text] [Related]
2. Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.
Yoshida S; Tanaka R; Takai N; Ono K
Cancer Res; 1988 Sep; 48(17):5011-6. PubMed ID: 3261631
[TBL] [Abstract][Full Text] [Related]
3. Intratumoral LAK cell and interleukin-2 therapy of human gliomas.
Barba D; Saris SC; Holder C; Rosenberg SA; Oldfield EH
J Neurosurg; 1989 Feb; 70(2):175-82. PubMed ID: 2643685
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant adoptive immunotherapy for pediatric recurrent brain tumors.
Lillehei KO; Johnson SD; McCleary EL; Mitchell DH; Schiltz PM; Kruse CA
Online J Curr Clin Trials; 1993 Dec; Doc No 111():[806 words; 5 paragraphs]. PubMed ID: 8305997
[No Abstract] [Full Text] [Related]
5. Improved long term survival after intracavitary interleukin-2 and lymphokine-activated killer cells for adults with recurrent malignant glioma.
Hayes RL; Koslow M; Hiesiger EM; Hymes KB; Hochster HS; Moore EJ; Pierz DM; Chen DK; Budzilovich GN; Ransohoff J
Cancer; 1995 Sep; 76(5):840-52. PubMed ID: 8625188
[TBL] [Abstract][Full Text] [Related]
6. Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results.
Tomita Y; Katagiri A; Saito K; Imai T; Saito T; Tanikawa T; Terunuma M; Nishiyama T; Takahashi K
Int J Urol; 1998 Jan; 5(1):16-21. PubMed ID: 9535595
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of patients with recurrent malignant gliomas treated with adjuvant adoptive immunotherapy.
Lillehei KO; Mitchell DH; Johnson SD; McCleary EL; Kruse CA
Neurosurgery; 1991 Jan; 28(1):16-23. PubMed ID: 1994273
[TBL] [Abstract][Full Text] [Related]
8. Adoptive immunotherapy with adherent lymphokine-activated killer (A-LAK) cells in glioblastoma multiforme.
Munari L; Silvani A; Passerini CG; Radrizzani M; Parmiani G; Boiardi A
J Neurosurg Sci; 1990; 34(3-4):283-8. PubMed ID: 1965907
[TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer lymphocytes: LAK and interleukin-2 in the treatment of malignancies of the central nervous system.
Blacklock JB; Grimm EA
Immunol Ser; 1989; 48():93-9. PubMed ID: 2488328
[No Abstract] [Full Text] [Related]
10. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor.
Tjota A; Zhang YQ; Piedmonte MR; Lee CL
J Urol; 1991 Jul; 146(1):177-83. PubMed ID: 2056587
[TBL] [Abstract][Full Text] [Related]
11. Effect of local administration of lymphokine-activated killer cells and interleukin-2 on malignant brain tumor patients.
Ibayashi Y; Yamaki T; Kawahara T; Daibo M; Kubota T; Uede T; Tanabe S; Hashi K
Neurol Med Chir (Tokyo); 1993 Jul; 33(7):448-57. PubMed ID: 7692323
[TBL] [Abstract][Full Text] [Related]
12. Local adoptive immunotherapy using lymphokine-activated killer cells and interleukin-2 against malignant pleural mesothelioma: report of two cases.
Yanagawa H; Sone S; Fukuta K; Nishioka Y; Ogura T
Jpn J Clin Oncol; 1991 Oct; 21(5):377-83. PubMed ID: 1753419
[TBL] [Abstract][Full Text] [Related]
13. Adoptive immunotherapy of a rat glioma using lymphokine-activated killer cells and interleukin 2.
Tzeng JJ; Barth RF; Clendenon NR; Gordon WA
Cancer Res; 1990 Jul; 50(14):4338-43. PubMed ID: 2364388
[TBL] [Abstract][Full Text] [Related]
14. [Adoptive immunotherapy in patients with malignant glioma].
Yoshida S; Takai N; Saito T; Tanaka R
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1930-2. PubMed ID: 3496052
[TBL] [Abstract][Full Text] [Related]
15. Combination of lymphokine-activated killer cells and interleukin-2 in treating metastatic renal cell carcinoma.
Fujioka T; Nomura K; Hasegawa M; Ishikura K; Kubo T
Br J Urol; 1994 Jan; 73(1):23-31. PubMed ID: 8298895
[TBL] [Abstract][Full Text] [Related]
16. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
[TBL] [Abstract][Full Text] [Related]
17. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y; Tanaka T; Tanji Y; Fujiwara A; Taguchi T
Biotherapy; 1994; 8(1):41-50. PubMed ID: 7547080
[TBL] [Abstract][Full Text] [Related]
18. Use of human leukocyte antigen-mismatched allogeneic lymphokine-activated killer cells and interleukin-2 in the adoptive immunotherapy of patients with malignancies.
Kimoto Y
Hum Cell; 1992 Sep; 5(3):226-35. PubMed ID: 1467321
[TBL] [Abstract][Full Text] [Related]
19. [Usefulness and limitation of immunotherapy of metastatic renal cell carcinoma with autologous lymphokine-activated killer cells and interleukin 2].
Nakano E; Iwasaki A; Seguchi T; Sugao H; Tada Y; Matsuda M; Sonoda T
Nihon Hinyokika Gakkai Zasshi; 1991 Mar; 82(3):395-404. PubMed ID: 2072602
[TBL] [Abstract][Full Text] [Related]
20. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases.
Keilholz U; Scheibenbogen C; Brado M; Georgi P; Maclachlan D; Brado B; Hunstein W
Eur J Cancer; 1994; 30A(1):103-5. PubMed ID: 8142149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
